Company Focus
Moderna
Latest Moderna News
Biotechnology
US mRNA specialist Moderna today announced Health Canada has approved mRESVIA (respiratory syncytial virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years of age and older. 8 November 2024
Related News
Insights
Company Spotlight
A biopharma company developing products for the treatment of human disease, including immunology, metabolism, cardiology and ophthalmology.
Latest News & Features of interest to Moderna
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk yesterday revealed that the CLARION-CKD Phase III trial failed to meet its primary endpoint and will be stopped. 27 June 2024
Biotechnology
US biotech Arrowhead Pharmaceuticals yesterday announced a reprioritization of funding for its research pipeline. 26 June 2024
Biotechnology
Mixed results for AstraZeneca's (LSE: AZN) Imfinzi (durvalumab) have been reported, with success in bladder cancer and a late-stage miss in lung cancer. 26 June 2024
Pharmaceutical
London-based pharma major GSK—one of the UK’s flagship companies—has suffered a galling defeat on home soil to US rival Pfizer. 25 June 2024
Pharmaceutical
RNA specialist Alnylam Pharmaceuticals (Nasdaq: ALNY) has revealed encouraging topline results from its Phase III HELIOS-B study. 24 June 2024
Biotechnology
Important research news last week included US liver disease biotech Mirum Pharmaceuticals reporting positive Phase IIb data on its volixibat in cholangitis. UK pharma major AstraZeneca released disappointing Phase III trial data on its breast cancer drug Truqap (capivasertib). Also, Denmark’s Zealand Pharma presented new data on its weight loss candidate petrelintide, an amylin agonist that could pitch itself against current blockbuster obesity treatments. On the regulatory front, the USA’s Sarepta Therapeutics received a welcome expanded indication from the US Food and Drug Administration (FDA) for its Duchenne muscular dystrophy drug Elevidys to cover older patient age groups. 23 June 2024
Biotechnology
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has approved Crysvita (burosumab) from Japanese drugmaker Kyowa Kirin. 21 June 2024
Latest In Brief for Moderna
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Latest Relevant Ones To Watch News
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
18 October 2024
24 September 2024
23 September 2024
16 September 2024
23 August 2024
22 August 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze